NASDAQ:ITMN InterMune (ITMN) Stock Price, News & Analysis → Your 'AI Income Playbook' Awaits... (From The Oxford Club) (Ad) Free ITMN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get InterMune alerts: Email Address Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About InterMune Stock (NASDAQ:ITMN)InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.Read More Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. ITMN Stock News HeadlinesSeptember 24, 2023 | fool.comInfinity Pharmaceuticals (NASDAQ: INFI)August 25, 2023 | thestreet.comWhy Ariad Pharmaceuticals (ARIA) Stock Is Up TodayMay 24, 2023 | finance.yahoo.comDo You Own a $10 Bill Worth $70,500?May 12, 2023 | reuters.comINTERMUNE, INC.March 29, 2023 | marketwatch.com2023 Kidney (Renal) Fibrosis Market Insights and Opportunities: Estimating CAGR and Revenue Growth by 2030January 2, 2023 | thestreet.comVertex Hep C Drug Improves Cure Rate in StudyDecember 31, 2022 | thestreet.comRoche Buying InterMune for $8.3 BillionNovember 27, 2022 | thestreet.com5 Things You Must Know Before the Market Opens WednesdayAugust 30, 2022 | thestreet.comStocks Turn Negative, Prolonging Dow's Trek Toward 20,000August 27, 2022 | thestreet.comA Biotech Stock Without the RiskJuly 24, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: A Remarkable MarketFebruary 22, 2022 | thestreet.comFive Billionaire-Owned Biotech Stocks You Could Acquire for 100%See More Headlines Receive ITMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterMune and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:ITMN CUSIP45884X10 CIK1087432 WebN/A Phone+1-415-4662200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key CompetitorsAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXRegeneron PharmaceuticalsNASDAQ:REGNGilead SciencesNASDAQ:GILDBiogenNASDAQ:BIIBView All Competitors ITMN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of InterMune own? Based on aggregate information from My MarketBeat watchlists, some companies that other InterMune investors own include Agios Pharmaceuticals (AGIO), Booking (BKNG), Alphabet (GOOG), Intercept Pharmaceuticals (ICPT), Align Technology (ALGN), Salesforce (CRM), 3D Systems (DDD), Gilead Sciences (GILD) and Illumina (ILMN). This page (NASDAQ:ITMN) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterMune Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share InterMune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.